Scientists search for keys to unlock immune attack on rare adrenal cancer

NCT ID NCT00457587

Ongoing Knowledge-focused Sponsor: University of Wuerzburg Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is not testing a new drug, but rather doing the early science needed to develop one. Researchers are looking for the right targets (antigens) on adrenocortical carcinoma cells and studying how the tumor suppresses the immune system. The goal is to find a way to create a vaccine or immunotherapy for this rare and aggressive cancer. The study includes 150 people with the cancer and healthy volunteers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this research could identify targets for a future vaccine or immunotherapy for adrenocortical carcinoma.
What could go wrong: This is a very early, preclinical study. It is not testing a treatment on patients, so it may not lead to a usable therapy. The findings may not translate into clinical benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADRENOCORTICAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adrenal carcinoma adrenal cortex carcinoma Cushing syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADRENOCORTICAL CARCINOMA CUSHING'S SYNDROME

Contacts and locations

Locations

Dept. of Medicine I, University of Wuerzburg

Würzburg, 97080, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.